Founder, BWS Financial Inc

Hamed Khorsand

Founder

Independent Stock Specific Research

BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Equity Bottom-Up

<ul>
<li>The third quarter was the first time PLx Pharma (PLXP) reported net sales of VAZALORE and they were above our forecast</li>
<li>PLXP had stayed quiet to the extent of the sales it would generate until the quarterly results were released. </li>
<li>Retailers stocked up ahead of the holidays and would clear out their current stock before making new purchases in January</li>
</ul>


The third quarter was the first time PLx Pharma (PLXP) reported net sales of VAZALORE and they were above our forecast
PLXP had stayed quiet to the extent of the sales it would generate until the quarterly results were released. 
Retailers stocked up ahead of the holidays and would clear out their current stock before making new purchases in January


<ul type="disc"><li>There is new medical opinion on the daily use of aspirin to prevent first heart attack or stroke affirming why there is market opportunity for VAZALORE even though the monthly price is greater than other aspirin options on the market. When we initiated coverage of PLx Pharma (PLXP) we had highlighted the growing concerns within the medical community of the risks associated with taking aspirin daily.</li></ul> <ul type="disc"><li>The U.S. Preventive Services Task Force said the health risks for patients 60 years old and older outweigh the benefits for taking a daily dose of aspirin. This is not the first-time daily aspirin regimen has come under scrutiny.</li></ul> <ul type="disc"><li>VAZALORE works by breaking up in the duodenum instead of the stomach. This is different than traditional aspirin and has shown clinical evidence of improved results.</li></ul> <ul type="disc"><li>We are emboldened by the medical community reaffirmation on traditional aspirin risks being a positive for VAZALORE and PLXP’s stock price. We would recommend owning shares of PLXP prior to the earnings release.</li></ul>

There is new medical opinion on the daily use of aspirin to prevent first heart attack or stroke affirming why there is market opportunity for VAZALORE even though the monthly price is greater than other aspirin options on the market. When we initiated coverage of PLx Pharma (PLXP) we had highlighted the growing concerns within the medical community of the risks associated with taking aspirin daily. The U.S. Preventive Services Task Force said the health risks for patients 60 years old and older outweigh the benefits for taking a daily dose of aspirin. This is not the first-time daily aspirin regimen has come under scrutiny. VAZALORE works by breaking up in the duodenum instead of the stomach. This is different than traditional aspirin and has shown clinical evidence of improved results. We are emboldened by the medical community reaffirmation on traditional aspirin risks being a positive for VAZALORE and PLXP’s stock price. We would recommend owning shares of PLXP prior to the earnings release.

<ul type="disc"><li>We are initiating coverage of PLx Pharma (PLXP) with a Buy Rating and $29 target.</li></ul> <ul type="disc"><li>PLXP is a combination of a management team with a successful launch history and a new drug delivery platform with its first FDA approved over the counter drug, aspirin without all the side effects.</li></ul> <ul type="disc"><li>PLXP launched VAZALORE, a recent FDA approved over the counter liquid filled aspirin, at the end of August in over 30 thousand retail pharmacy shelves.</li></ul> <ul type="disc"><li>The investment story has been de-risked from the beginning year. PLXP received FDA approval to begin commercialization of VAZALORE. PLXP has achieved product placement at major retailers at the onset of the product launch with preferred shelf placement at most stores.</li></ul> <ul type="disc"><li>PLXP should grow revenue steadily as consumer awareness for VAZALORE widens.</li></ul> <ul type="disc"><li>The achievement in removing the biggest barrier to taking aspirin could result in PLXP quickly becoming a target of a larger pharmaceutical company.</li></ul>

We are initiating coverage of PLx Pharma (PLXP) with a Buy Rating and $29 target. PLXP is a combination of a management team with a successful launch history and a new drug delivery platform with its first FDA approved over the counter drug, aspirin without all the side effects. PLXP launched VAZALORE, a recent FDA approved over the counter liquid filled aspirin, at the end of August in over 30 thousand retail pharmacy shelves. The investment story has been de-risked from the beginning year. PLXP received FDA approval to begin commercialization of VAZALORE. PLXP has achieved product placement at major retailers at the onset of the product launch with preferred shelf placement at most stores. PLXP should grow revenue steadily as consumer awareness for VAZALORE widens. The achievement in removing the biggest barrier to taking aspirin could result in PLXP quickly becoming a target of a larger pharmaceutical company.

PLXP: Band Back Together, Initiating with Buy

United States

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company developing aspirin products that use its patented drug delivery system, which targets delivery of APIs to various portions of the gastrointestinal tract. This has the potential to improve the absorption of many drugs and to reduce acute GI side effects associated with aspirin and ibuprofen, and potentially other drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PLx Pharma (PLXP US)

PLXP: Investing in Growth

PLXP reported its first sales results from VAZALORE. Sales were higher than expectations due to seasonal stocking. Q4 sales is expected to bring...

BWS Financial Inc

PLXP: Headlines to Buy

News headlines of medical opinion on taking aspirin daily should be construed as a positive for PLXP and its drug VAZALORE. Negative opinion on...

BWS Financial Inc

PLXP: Band Back Together, Initiating with Buy

PLXP has begun commercialization of an FDA approved over the counter liquid aspirin capsule that has shown to have greater absorption and none of...

BWS Financial Inc

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)